DoD Tick-Borne Disease Idea Award

The summary for the DoD Tick-Borne Disease Idea Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Tick-Borne Disease Idea Award: The FY16 TBDRP Idea Award promotes new ideas that represent innovative approaches to Lyme disease and other tick-borne disease research and have the potential to make an important contribution to the TBDRP mission. This award funds conceptually innovative, high-risk/ potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by Lyme disease and/or other tick-borne illnesses. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.
The following are important aspects of the FY16 TBDRP Idea Award:
• Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to Lyme disease and other tick-borne disease research. Research that is merely an incremental advance (the next logical step) is not considered innovative.
• Preliminary Data: Due to this award’s emphasis on innovation, unpublished data from the laboratory of the Principal Investigator (PI) or collaborators named on the application, and/or data from the published literature that are relevant to Lyme disease and other tick-borne diseases and support the proposed research project are encouraged, but not required.
• New Investigators: The FY16 TBDRP Idea Award mechanism encourages applications from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicants still early in their faculty appointments, or in the process of developing independent research careers, to also compete for funding and bring new, innovative ideas to Lyme disease and other tick-borne disease research. Applications from New Investigators and Established Investigators will be grouped separately for peer and programmatic reviews, with personnel evaluated by distinct peer review criteria dependent on the category designated. PIs applying under the New Investigator category are strongly encouraged to strengthen their applications through collaboration with investigators experienced in Lyme disease and other tick-borne disease research and/or possessing other relevant expertise as demonstrated by a record of funding and publications. It is the responsibility of the PI to describe how the collaboration(s) will augment his or her expertise to best address the research question. All New Investigator applicants must meet specific eligibility criteria as described in
Section I.D., Eligibility Information.
Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this Program Announcement/Funding Opportunity. A clinical trial is defined as a prospective accrual of patients in which an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm.